How Mushroom Antioxidants Can Alleviate Menstrual Pain by Targeting Uterine Cells

New Scientist - Your source for science news and expert analyses in technology, health, and the environment.

Hot Water Bottles: An Effective Solution for Menstrual Cramps

Carol Yepes/Getty Images

Research suggests that antioxidants found in medicinal mushrooms may help alleviate menstrual pain. Taking daily supplements containing L-ergothioneine—also present in fermented foods—may not only curb existing discomfort but also reduce overall pain by interacting with uterine cells.

“Instead of waiting to address severe pain, EGT [L-ergothioneine] may offer foundational nutritional support, reducing reliance on potent medications and providing a safer pathway for women’s health,” explains Guohua Xiao from Gene III Biotechnology, Nanjing, China.

Menstrual pain, known as dysmenorrhea, ranks among the most prevalent gynecological issues. Prevalence reports range widely from 16% to 91%. This discomfort is often linked to the uterus releasing high levels of inflammatory chemicals called prostaglandins, which cause forceful contractions to shed the lining, sometimes compressing nearby blood vessels and cutting off oxygen supply to muscle tissue.

Dysmenorrhea is also associated with oxidative stress, an imbalance between free radicals and antioxidants in the body that leads to cellular damage.

Current guidelines suggest pain relievers like ibuprofen, which inhibit inflammation and prostaglandin production. Hsiao and his research team hypothesized that L-ergothioneine could provide protective benefits by mitigating oxidative stress in the uterus.

In their investigation, Hsiao and colleagues enlisted 40 women aged 18 to 30 diagnosed with primary dysmenorrhea. None had used painkillers or herbal treatments within the previous month.

Half received 120 milligrams of L-ergothioneine daily for three menstrual cycles, while the rest were given a placebo.

Those taking the supplement reported an initial average pain level of 4.8 out of 10, which decreased significantly over three cycles to scores of 4.1, 3.6, and 2.3. L-ergothioneine’s cell accumulation may enhance its efficacy over time, remarked Hsiao. In contrast, the placebo group did not experience notable pain relief.

The team observed no significant differences in inflammation levels between the experimental and control groups. This aligns with Xiao’s assertion that L-ergothioneine operates via a unique pathway, diverging from traditional pain relief methods. “Menstrual discomfort largely originates from local oxidative stress in uterine tissue. The absence of systemic anti-inflammatory responses suggests a localized antioxidant activity. EGT may directly neutralize free radicals at the source before triggering a systemic inflammatory cascade,” he explained.

Andrea Meyer, a researcher at the University of Melbourne, finds these findings plausible but underscores the necessity for larger studies. “It’s an avenue worth exploring,” she remarked. Hsiao’s team aims to conduct a large-scale multi-center trial soon.

This approach will enhance our understanding of L-ergothioneine’s safety profile, although initial results showed no side effects in either group. Long-term usage of conventional pain relief medications like ibuprofen is linked to increased risks of heart issues and kidney failure and stomach ulcers. Hsiao noted that the cellular transport mechanism of L-ergothioneine ensures it is excreted by the kidneys after reaching saturation.

Topics:

Source: www.newscientist.com

Time to reconsider the impact of uterine fibroids, a widespread silent epidemic among women with 70% affected

Are you familiar with uterine fibroids? It’s not surprising if you’re not, as they are not widely discussed. However, they can affect 70-80% of women by age 50. Despite being more prevalent among Black women, women of color are often underdiagnosed.

Uterine fibroids are growths of muscle and fibrous tissue in the uterus, typically occurring in women aged 30-50. These fibroids can vary in size and shape and can be found in different layers of the uterus, leading to various symptoms.

Although referred to as “benign” tumors by doctors, uterine fibroids can still cause numerous issues, such as heavy menstruation, lower abdominal pain, and pressure on other organs when they grow large enough.

https://c02.purpledshub.com/uploads/sites/41/2025/01/fibroids.mp4
A CT scan showing a large solid mass in the uterus, indicating a uterine fibroid

Uterine fibroids are influenced by genetics, family history, and ethnicity, as well as hormones like estrogen and progesterone, which stimulate their growth. While pregnancy can lead to an increase in fibroid size due to higher hormone levels, they are commonly detected through ultrasound scans.

Treatment options for uterine fibroids vary based on symptoms and pregnancy plans. Some women may opt for monitoring small, asymptomatic fibroids, while others may choose drug therapy to reduce hormone levels and shrink the fibroids.

Surgical treatments like myomectomy or hysterectomy can also be considered, but these may not be suitable for women looking to conceive. Uterine fibroids can significantly impact pregnancy, increasing the risk of complications like miscarriage and premature birth.

Despite available treatments, awareness of uterine fibroids remains low. Increasing awareness about menstrual health and pregnancy complications is crucial for timely and effective treatment.

Source: www.sciencefocus.com

Uterine fluid-based organoids show promise for treating unborn fetuses

A ball of cells grown from amniotic fluid. Red indicates lung stem cells

Giuseppe Cara, Paolo di Coppi, Mattia Guerli

Babies born with serious medical conditions may one day receive better diagnosis and treatment in utero, thanks to a new technique that takes samples of cells from intrauterine fluid and grows them in dishes. It might become.

world's first, paolo de coppi Researchers at Great Ormond Street Hospital in London have shown that fetal cells from amniotic fluid can be induced to form miniature spheres of lung, kidney or small intestine tissue. They also showed that these lung organoids could help treat babies born with a sometimes fatal lung disease called congenital diaphragmatic hernia (CDH).

Although the technique has not yet been used to treat children, the results show it is possible in principle, De Coppi said. The strategy, which researchers call “personalized prenatal medicine,” can also be modified to help treat a variety of other congenital conditions.

The idea takes advantage of a recent approach in which cells in a dish are induced to grow into lentil-sized tissue organoids that take on a three-dimensional structure. These are better than standard techniques of growing cells in two-dimensional layers to capture specific aspects of the tissue in question, such as whether the tissue is healthy or growing abnormally.

The researchers now show that samples of amniotic fluid taken during pregnancy contain fetal cells that can form tissue organoids for the lungs, kidneys, and small intestine.

Studying organoids made from cells from fetuses known to suffer from congenital disorders can tell doctors exactly what form they take, how severe they are, and how they can be treated. We may be able to provide further information.

The researchers created organoids for 12 fetuses with CDH, which causes abdominal organs to push up into the chest, preventing the left lung from growing properly. This condition can be treated by pushing a balloon into the baby's lungs while the baby is in the womb to expand the lungs and improve growth.

The researchers created lung organoids from the fetuses before and after balloon treatment. They found hints that the organoids created after the treatment behaved more like healthy lung tissue than those created beforehand, suggesting that the treatment was successful.

Therefore, organoid technology can be used not only to monitor whether a treatment is effective, as doctors perform this intervention only in the most severe cases, but also to determine whether treatment is needed in the first place. You can use it.

“This has great potential for functional diagnostics,” says De Coppi. “We know how to make diagnoses based on images, but sometimes there are extensive diagnoses. [condition severity] Possible. We want to provide better prenatal diagnostic tools. ”

“If we can classify a disease as mild, moderate, or severe, that's a huge accomplishment,” he says. Cecilia Goeterstrom At Karolinska Institutet, Stockholm, Sweden.

holm schneider Researchers at Germany's Erlangen University Hospital say their approach suggests that organoids could one day be converted into mature tissue and transplanted into babies after birth, even if part of their intestine is missing, for example. ing. “If we could engineer gut-like structures for these children to use after birth, we would be in a much better position,” he says.

topic:

Source: www.newscientist.com